CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo

Area of Science:

• Immunology
• B cell biology
• Molecular interactions

Background:

• CD22 is a B lymphocyte receptor that interacts with alpha2,6-linked sialic acid ligands.
• Understanding CD22's role in B cell function in vivo is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the in vivo effects of inhibiting CD22 ligand binding on B cell function and survival.
• To explore the potential of targeting CD22 ligand interactions for therapeutic intervention.

Main Methods:

• Generation of mouse anti-mouse CD22 monoclonal antibodies (mAbs) with varying degrees of CD22 ligand binding inhibition.
• Assessment of B cell turnover, survival, and numbers in blood, spleen, and lymph nodes following mAb administration.
• Evaluation of CD22 internalization, marginal zone B cell depletion, and recirculating B cell reduction.
• Studies in CD22AA mice with mutated CD22 to confirm the mechanism of action.

Main Results:

• CD22 ligand-blocking mAbs significantly accelerated mature B cell turnover (2-4 fold) in multiple lymphoid organs.
• These mAbs inhibited the survival of both normal and malignant B cells in vivo.
• Significant CD22 internalization and depletion of marginal zone B cells (82-99%) were observed.
• Reduced mature recirculating B cell numbers (75-85%) were noted, independent of complement and FcRs.

Conclusions:

• Inhibition of CD22 ligand binding disrupts normal and malignant B cell survival in vivo.
• Targeting CD22 ligand binding domains represents a novel therapeutic strategy for B cell malignancies.
• CD22-mediated B cell regulation is critical for maintaining B cell homeostasis.